BIVI Research Note — Evidence Before Optimism
BioVie’s subgroup signal does not resolve the missing registered endpoint or the scale of pending dilution.
BIVI
BIVI Deep Coverage Review — Analysis as of August 7, 2026
BIVI offers a covered 6.75% yield and fixed-rate debt, while Caesars lease uncertainty keeps tenant concentration at the center of the thesis.
BIVI Research Note — Evidence Before the Headline
BioViespeed fell to $20.06, while negative gross margin and a larger share count leave the recovery thesis dependent on fresh factory evidence.
BIVI Deep Coverage Review — Analysis as of July 31, 2026
BioViespeed’s lower share price does not repair negative gross margin, weak utilization or dilution risk ahead of the next operating update.
BIVI Research Note — Clinical Optionality Meets Financing Pressure
BioVie’s Phase 2 optionality faces going-concern pressure, fragile liquidity and persistent weakness against the broader biotechnology group.
BIVI Deep Coverage Review — Analysis as of July 24, 2026
BioVie’s two Phase 2 readouts face a prior late-stage failure, funding pressure, fragile liquidity and persistent weakness versus biotech peers.